Abstract 779P
Background
HRD is used to identify HGOC patients most likely to benefit from PARPi. Unlike commercially available genomic scar HRD tests (CT), functional testing by RAD51, have potential to provide a real-time readout of actual HR status and may be more reliable to detect HRD.
Methods
This single-institution study assesses the immunofluorescence-based RAD51 foci test and correlates it to CT and treatment outcomes in newly diagnosed advanced HGOC pts between 2020-2023. Tumors with <10% RAD51+ tumor cells in S/G2-phase were classified as HRD positive (HRD+). HRD status agreement rate between CT and RAD51 was calculated. Median progression-free survival (mPFS) was estimated in each subgroup.
Results
Overall, 53 pts had CT and RAD51 tests performed on archival tumour samples. Both tests were contributive for 38 pts. As 1st line therapy, all pts received platinum chemotherapy. As maintenance, 47% received PARPi and 18% Bevacizumab alone. % of HRD+ according CT and RAD51 was 55.3% (21/38) and 42.1% (16/38), respectively. Concordance rate between both tests was 50% (95%CI 34.8-65.2), with 12 and 7 pts identified as HRD+ only by CT and RAD51. Table: 779P
HRD test | HRD RAD51 | HRP RAD51 |
HRD CT | 9 | 12 |
HRP CT | 7 | 10 |
Based on CT, mPFS of HRD+ and HRP pts was 19.4m and 16.1m, respectively (HR 0.69; 95%CI, 0.26-1.85). Based on RAD51, mPFS for HRD and HRP pts was 19.4m and 14.3m (HR 0.70; 95%CI, 0.25-1.93), respectively. Among pts with consistent HRD test results, mPFS was 19.4 m and 11 m for HRD and HRP pts, respectively. Among disparate results, mPFS was 17.4m and 16.1m for pts defined as HRD only by CT and RAD51, respectively.
Conclusions
Our preliminary data showed both tests identified HRD and HRP subpopulations with similar outcomes despite low correlation between them. Among pts with HRP by CT, RAD51 identified a subset of HRD+ with better mPFS. Combination of genomic and functional HRD tests could improve molecular diagnostic accuracy of HGOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
VHIO.
Disclosure
C. Garcia Duran: Financial Interests, Principal Investigator: AstraZeneca; Financial Interests, Speaker’s Bureau: GSK. G. Villacampa Javierre: Financial Interests, Personal, Invited Speaker, Invited speaker in a course: MSD; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Invited Speaker, Invited speaker in an internal training: Pierre Fabrer, GSK; Financial Interests, Personal, Invited Speaker, Internal discussion about the interpretation of some published results: Pfizer; Financial Interests, Personal, Other, Collaborations with specific projects: Reveal Genomics. L. Fariñas Madrid: Financial Interests, Invited Speaker: AstraZeneca; Financial Interests, Speaker’s Bureau: GSK. D.G. Illescas: Financial Interests, Invited Speaker: GSK. V. Serra Elizalde: Financial Interests, Research Grant: Novartis. A. Llop-Guevara: Financial Interests, Research Grant: PharmaMar. A. Oaknin: Financial Interests, Personal, Advisory Board: AstraZeneca, Clovis Oncology, Deciphera Pharmaceuticals, Genmab, GSK, Immunogen, Mersana Therapeutics, PharmaMar, Merck Sharps & Dohme de España, SA, Agenus, Sutro, Corcept Therapeutics, EMD Serono, Novocure, Sattucklabs, Itheos, Eisai, F. Hoffmann-La Roche, Seagen, OneXerna Therapeutics, Inc., Regeneron, Sutro Biopharma; Financial Interests, Personal, Other, Travel and accomodation: AstraZeneca, PharmaMar, Roche; Financial Interests, Institutional, Funding: Amgen, AbbVie Deutschland, Advaxis Inc., Aeterna Zentaris, Aprea Therapeutics AB, Regeneron Pharmaceuticals, Clovis Oncology Inc., EISAI limited Ltd., F. Hoffmann-La Roche Ltd., Immunogen Inc., Merck, Sharp & Dohme de España SA, Millennium Pharmaceuticals Inc., PharmaMar SA, Tesaro Inc., Bristol Myers Squibb; Non-Financial Interests, Leadership Role, on behalf of GEICO: GCIG; Non-Financial Interests, Officer, Chair of Gynaecological Track ESMO 2019 . Scientific Track Member Gynaecological Cancers ESMO 2018 , ESMO 2020 , ESMO 2022 . Member of Gynaecological Cancers Faculty and Subject Editor Gyn ESMO Guidelines: ESMO; Non-Financial Interests, Leadership Role, ESMO GYN Co-Chair 2023-2025: ESMO; Non-Financial Interests, Leadership Role, Chair de Cervix Committee. 2022-2024: GCIG; Non-Financial Interests, Member: ESMO, ASCO, GCIG, SEOM, GOG. All other authors have declared no conflicts of interest.
Resources from the same session
758P - Phase II trial evaluating the efficacy of pembrolizumab combined with vorinostat in patients with recurrent and/or metastatic vulvar and vaginal squamous cell carcinoma: Subgroup analysis of the PEVOsq basket trial
Presenter: Mathilde Saint-Ghislain
Session: Poster session 11
759P - Nimotuzumab combined with concurrent chemo-radiotherapy in patients with locally advanced cervical squamous cell carcinoma: A randomized, controlled, open-label, multicenter study
Presenter: Junjie Wang
Session: Poster session 11
760P - Efficacy and safety of nimotuzumab plus radiotherapy for elderly patients with locally advanced cervical squamous cell carcinoma
Presenter: Ang Qu
Session: Poster session 11
761P - A phase II trial of avelumab in combination with pegylated liposomal doxorubicin in recurrent/metastatic endometrial cancer (GEICO 70-E): analysis according to molecular classification
Presenter: Josep M. Piulats
Session: Poster session 11
764P - Tislelizumab (Anti-PD-1) combined with definitive chemoradiotherapy in recurrent and/or metastatic cervical cancer (PILOT-2020-511): A single-arm, phase II trial
Presenter: JUN ZHU
Session: Poster session 11
765P - SABRINA study: A phase II study of senaparib monotherapy for patients (pts) with BRCA1/2 mutated recurrent platinum-sensitive ovarian cancer (PSOC)
Presenter: Xiaohua Wu
Session: Poster session 11
766P - A comparative study of sequential and interdigitated brachytherapy with chemoradiation in patients of locally advanced carcinoma cervix
Presenter: Shreya Singh
Session: Poster session 11
767P - Phase I/II study of toripalimab with cisplatin-based concurrent IMRT for local advanced cervical cancer
Presenter: Ping Jiang
Session: Poster session 11